Nasdaq

Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes

Sanofi SNY announced that the European Commission has approved Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes (T1D) in patients aged eight years and older with stage 2 disease.
Nasdaq

BridgeBio Pharma Receives EU Approval for Acoramidis, the First Treatment for ATTR-CM with Near-Complete TTR Stabilization

BridgeBio Pharma announced that the European Commission has granted marketing authorization for acoramidis, branded as BEYONTTRA™, to treat wild-type or variant transthyretin amyloidosis with ...
Seeking Alpha

Press Release: Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes

Approval based on the TN-10 phase 2 study that demonstrated a significant delay of onset of stage 3 T1D in stage 2 T1D patients Teizeild represents a potential significant change in the treatment of ...